K

    Kiora Pharmaceuticals Inc (KPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.51
    -0.11 (-4.20%)

    Market Cap: $11.59M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +0.24%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.38
    Range$-0.38 - $-0.38
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.69-81.6%
    60d ago$-0.69-81.6%
    30d ago$-0.69-81.6%
    7d ago$-0.69-81.6%
    Current$-0.38
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$0.04
    Range$0.04 - $0.04
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.04---
    Sep 26EST
    		-$-0.38---
    Jun 26
    		$-0.34$-0.62+45.16%Beat+37.0%
    Mar 26
    		$-0.58$-0.71+18.31%Beat-11.5%
    Dec 25
    		$-1.73$-0.44-293.70%Miss-43.4%
    Sep 25
    		$0.01N/A+101.39%Beat+101.2%
    Jun 25
    		$-0.54$-0.58+6.90%Beat-1.9%
    Mar 25
    		$-0.52$-0.77+32.47%Beat-115.2%
    Dec 24
    		$-1.21$-0.74-63.19%Miss-156.9%
    Sep 24
    		$-0.81$-0.81+0.00%Beat+89.9%
    Jun 24
    		$-0.53$-0.88+39.77%Beat+92.5%
    Mar 24
    		$3.42$2.48+37.90%Beat+138.0%
    Dec 23
    		$-0.47$-0.42-11.90%Miss+73.3%
    Sep 23
    		$-8.01$-3.10-158.39%Miss+79.6%
    Jun 23
    		$-7.11$-9.59+25.86%Beat+89.0%
    Mar 23
    		$-9.00N/A+55.75%Beat+79.2%
    Dec 22
    		$-1.76$-2.46+28.46%Beat-166.7%
    Sep 22
    		$-39.18$-25.83-51.68%Miss+62.5%
    Jun 22
    		$-64.80$-72.00+10.00%Beat+48.6%
    Mar 22
    		$-43.20$-82.80+47.83%Beat+67.6%
    Dec 21
    		$-0.66$-0.30-120.00%Miss+96.8%
    Sep 21
    		$-104.40$-121.20+13.86%Beat+34.1%
    Jun 21
    		$-126.00$-150.00+16.00%Beat+7.9%
    Mar 21
    		$-133.20$-138.60+3.90%Beat-30876.7%
    Dec 20
    		$-20.80$-17.60-18.18%Miss+92.4%
    Sep 20
    		$-158.40$-151.20-4.76%Miss+61.7%
    Jun 20
    		$-136.80$-154.80+11.63%Beat+36.7%
    Mar 20
    		$-0.43N/AN/ABeat-100.8%
    Dec 19
    		$-273.60$-291.60+6.17%Beat-812.0%
    Sep 19
    		$-414.00$-270.00-53.33%Miss-9.5%
    Jun 19
    		$-216.00$-270.00+20.00%Beat+42.9%
    Mar 19
    		$54.00N/A+120.00%Beat+107.1%
    Dec 18
    		$-30.00$-36.00+16.67%Beat+66.7%
    Sep 18
    		$-378.00$-405.00+6.67%Beat+70.8%
    Jun 18
    		$-378.00$-702.00+46.15%Beat+75.0%
    Mar 18
    		$-756.00$-1269.00+40.43%Beat+50.0%
    Dec 17
    		$-90.00$-144.00+37.50%Beat+60.5%
    Sep 17
    		$-1296.00$-1170.00-10.77%Miss+33.3%
    Jun 17
    		$-1512.00$-1044.00-44.83%Miss-
    Mar 17
    		$-1512.00$-1962.00+22.94%Beat-
    Dec 16
    		$-228.00$-254.00+10.24%Beat-
    Sep 16
    		$-1944.00$-2376.00+18.18%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.95EV/EBITDA-1.03x
    Price/FCF-1.80xFCF Yield-55.55%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-56.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage206.49x
    Current Ratio8.97xQuick Ratio8.97x
    Trading Statistics
    Beta-0.34Avg Volume17.52K
    52-Week High$2.9552-Week Low$1.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.62
    SMA 20$2.60
    SMA 50$2.57
    SMA 200$2.32
    EMA 10$2.60
    EMA 20$2.60
    EMA 50$2.57
    EMA 200$2.49

    MACD

    Line: 0.01Signal: 0.02Hist: -0.01

    ADX

    ADX: 12.5+DI: 23.0-DI: 24.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down24.0
    PSAR$2.75

    Bollinger Bands

    Upper Band$2.72
    Lower Band$2.48
    %B Position919%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    43.7

    Momentum Oscillators

    Stoch %K43.2
    Stoch %D48.6
    Williams %R-88.9
    ROC (10d)-3.1%
    Momentum-0.08
    CCI (20d)-110.9
    MFI (14d)48.4

    Volatility Measures

    ATR (14d)$0.10(4.1%)
    StdDev (20d)0.06
    Hist Vol41.8%(High)

    Volume Flow

    VWAP$2.52
    OBV50.3M
    AD Line-15.3M
    CMF (20d)0.216

    Volume Metrics

    Avg Vol (20d)18.1K
    Vol Ratio0.8x
    VWMA (20d)$2.58

    Pivot Points

    R3$2.70
    R2$2.69
    R1$2.65
    Pivot Point$2.64
    S1$2.60
    S2$2.59
    S3$2.55

    Advanced Oscillators

    TSI3.18
    Ultimate Osc53.6
    KST22.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$-15,951,822$0$20,000$16.00M$283,872$0
    Cost of Revenue$0$0$10,508$0$0$0$34,089$0$0$0$7,935$0
    Gross Profit$0$0$-10,508$0$0$0$-15,985,911$0$20,000$16.00M$-7,935$0
    Operating Expenses$2.21M$2.51M$7.31M$794,437$2.40M$2.33M$2.56M$3.60M$2.56M$2.78M$2.12M$5.92M
    R&D$2.08M$2.12M$2.93M$2.73M$2.59M$2.53M$1.92M$2.18M$2.05M$1.68M$1.11M$1.09M
    SG&A$1.38M$1.61M$1.46M$1.44M$1.35M$1.49M$1.33M$1.38M$1.54M$1.30M$880,550$1.42M
    Operating Income$-2,213,771$-2,510,195$-7,310,085$-794,437$-2,396,196$-2,330,354$-2,564,682$-3,602,237$-2,544,887$13.22M$-2,118,649$-5,918,568
    Interest Income$146,232$139,338$190,310$201,822$225,237$276,633$438,860$248,840$342,102$223,047$0$49,912
    Interest Expense$0$0$0$0$0$0$0$0$0$0$59,638$0
    Income Before Tax$-2,079,010$-2,417,984$-7,166,490$-616,323$-2,264,516$-2,069,974$-2,158,497$-3,413,326$-2,221,646$13.45M$-2,178,287$-5,762,941
    Income Tax Expense$0$0$-649,969$-643,129$-112,057$123,006$2.07M$0$0$0$0$0
    Net Income$-2,079,010$-2,417,984$-6,516,521$26,806$-2,152,459$-2,192,980$-4,223,502$-3,413,326$-2,221,646$13.45M$-2,268,606$-5,762,941
    EBITDA$-2,214,501$-2,546,759$-7,326,332$-807,593$-2,486,330$-2,346,289$-2,569,999$-3,660,071$-2,557,419$13.24M$-2,204,745$-5,801,545
    EBIT$-2,225,242$-2,557,322$-7,336,840$-818,145$-2,489,753$-2,346,607$-2,575,911$-3,662,166$-2,563,748$13.23M$-2,212,680$-5,812,853
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KPRX

    News

    Price to sales forward of Kiora Pharmaceuticals, Inc. – OTC:KPHMW

    This article provides a brief financial overview for Kiora Pharmaceuticals, Inc. (OTC:KPHMW), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were recorded. The content seems to be a placeholder or a very minimal financial data point from a larger platform.

    TradingView•8/23/26•
    Neutral

    Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com

    This article from Investing.com announces a Form 8K filing by Kiora Pharmaceuticals Inc. for August 19. It also includes a standard disclaimer about the risks involved in trading financial instruments and cryptocurrencies, emphasizing market volatility and the importance of informed investment decisions.

    Investing.com Australia•8/19/26•
    Neutral

    Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com

    This article from Investing.com reports on Kiora Pharmaceuticals Inc.'s Form 8K filing for August 19. The brief piece indicates that this filing is a standard regulatory announcement, typical for publicly traded companies. No specific details about the content of the Form 8K are provided within the article itself, but it does include Kiora Pharmaceuticals' stock symbol, KPRX.

    Investing.com Nigeria•8/19/26•
    Neutral

    Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com

    This article announces the filing of a Form 8K by Kiora Pharmaceuticals Inc. on August 19. It provides no further details about the content of the filing but links to the company's stock information. The remainder of the page consists of general financial market data, news headlines, and promotional content from Investing.com.

    Investing.com Australia•8/19/26•
    Neutral

    10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301

    Kiora Pharmaceuticals licensed the South Korean development and commercialization rights for its retinal therapy KIO-301 to Chong Kun Dang Pharmaceutical for an upfront payment of $1 million, plus potential milestones and royalties. This agreement covers the last major unpartnered market for KIO-301, allowing Kiora to focus internal resources on other programs. KIO-301, a molecular photoswitch designed to restore light sensitivity in degenerated retinal cells, will advance into a single global Phase 3 trial coordinated by its partners, addressing retinitis pigmentosa which affects over 10,000 people in South Korea.

    Stock Titan•8/19/26•
    Bullish

    Frequently Asked Questions About KPRX

    Does KPRX pay dividends?
    Kiora Pharmaceuticals Inc (KPRX) does not currently pay a regular dividend.
    What is KPRX's market cap?
    Kiora Pharmaceuticals Inc (KPRX) has a market capitalization of $11.59M with a current stock price of $2.51.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In